Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | KDM4E | B2RXH2 | 2/20 | 0.43 |
| ▸ | GAA | P10253 | 2/20 | 0.43 |
| ▸ | PDPK1 | O15530 | 1/20 | 0.43 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.43 |
| ▸ | MAPK10 | P53779 | 2/20 | 0.41 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.41 |
| ▸ | ALPL | P05186 | 1/20 | 0.41 |
| ▸ | IDO1 | P14902 | 1/20 | 0.41 |
| ▸ | HPGD | P15428 | 1/20 | 0.41 |
| ▸ | TTK | P33981 | 1/20 | 0.41 |
| ▸ | LRRK2 | Q5S007 | 4/20 | 0.40 |
| ▸ | ULK1 | O75385 | 1/20 | 0.38 |
| ▸ | NPC1 | O15118 | 1/20 | 0.38 |
| ▸ | RAB9A | P51151 | 1/20 | 0.38 |
| ▸ | FGFR1 | P11362 | 2/20 | 0.38 |
| ▸ | ITK | Q08881 | 1/20 | 0.38 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.38 |
| ▸ | PDE10A | Q9Y233 | 1/20 | 0.38 |
| ▸ | FLT1 | P17948 | 1/20 | 0.37 |
| ▸ | GSK3A | P49840 | 1/20 | 0.37 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL30619334 | 1.00 | KDM4E (0.43) | KDM4EGAAPDPK1CYP3A4MAPK10 | |
| SCHEMBL5562284 | 0.90 | KDM4E (0.41) | KDM4EGAAPDPK1CYP3A4MAPK10 | |
| SCHEMBL3057752 | 0.88 | KDM4E (0.50) | KDM4EGAAPDPK1CYP3A4MAPK10 | |
| SCHEMBL15485748 | 0.84 | KDM4E (0.47) | KDM4EGAAPDPK1CYP3A4MAPK10 | |
| SCHEMBL4004747 | 0.84 | RAB9A (0.48) | KDM4EGAAPDPK1CYP3A4MAPK10 | |
| SCHEMBL30611180 | 0.83 | LRRK2 (0.53) | KDM4EALDH1A1HPGDLRRK2FGFR1 | |
| SCHEMBL25270970 | 0.83 | KDM4E (0.46) | KDM4EGAAPDPK1CYP3A4MAPK10 | |
| SCHEMBL29869220 | 0.81 | HTR2C (0.50) | KDM4EGAAPDPK1CYP3A4MAPK10 | |
| SCHEMBL1545976 | 0.81 | HTR2C (0.50) | KDM4EGAAPDPK1CYP3A4MAPK10 | |
| SCHEMBL6635919 | 0.80 | KDM4E (0.38) | KDM4EGAAPDPK1CYP3A4MAPK10 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-4612128-A1 | COMPOUNDS AND THEIR USE FOR TREATMENT OF HEMOGLOBINOPATHIES | Bristol-Myers Squibb Company (US) | 2025-09-10 | — | — | EP | disclosed |
| WO-2024097932-A1 | COMPOUNDS AND THEIR USE FOR TREATMENT OF HEMOGLOBINOPATHIES | BRISTOL-MYERS SQUIBB COMPANY (US) | 2024-05-10 | — | — | WO | disclosed |
| US-20040167158-A1 | Heterocyclic compounds for the treatment of migraine | NPS ALLELIX BIOPHARMACEUTICALS, INC. (CA) | 2004-08-26 | — | — | US | disclosed |
| US-6716837-B1 | INDOLE AND INDAZOLE COMPOUNDS | NPS ALLELIX BIOPHARMACEUTICALS, INC. (CA) | 2004-04-06 | — | — | US | disclosed |
| EP-1196380-A2 | INDOLES AND INDAZOLES FOR THE TREATMENT OF MIGRAINE | NPS Allelix Corp. (CA) | 2002-04-17 | — | — | EP | disclosed |
| WO-2001005758-A2 | INDOLES AND INDAZOLES FOR THE TREATMENT OF MIGRAINE | NPS ALLELIX CORP. (CA) | 2001-01-25 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20040167158-A1 | Heterocyclic compounds for the treatment of migraine | SCN7A, CNR2, HTR7 | KDM4E 2619/4885GAA 4547/4885PDPK1 4390/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.